What Is It, and Why Does It Matter?
Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21). It trains your immune system to recognize 21 types of Streptococcus pneumoniae, a germ that can cause pneumonia, meningitis, and serious blood infections. The FDA added a new use for children and teens ages 2 through 17 who have finished their primary pneumococcal series and have medical conditions that raise their risk of pneumococcal disease.
With this decision, Capvaxive is the only pneumococcal conjugate vaccine in the U.S. that has been specifically studied and cleared for this higher-risk pediatric group. This medicine is also cleared in adults 18 and older to help prevent invasive disease and pneumonia.
Children and teens with higher risk have a greater chance of severe illness from these infections. Capvaxive is designed to add protection on top of the standard childhood pneumococcal shots by including strains that are not in those primary vaccines. Based on national surveillance data summarized by the drugmaker, the strains in Capvaxive are linked to about 79% of invasive pneumococcal disease in higher-risk children. This describes strain coverage and does not measure how well the vaccine prevents illness.
Conjugate vaccines attach pieces of the bacteria to a carrier protein. This helps your body build strong B- and T-cell immune memory, which supports lasting protection. In studies in adults, this medicine triggered strong immune responses to strains not covered by similar vaccines. Responses in adults 18 to 49 were similar to or higher than those seen in adults 50 to 64. Together with pediatric findings, this data suggests broader strain coverage with solid immune responses across the ages studied.
Why Was It Approved?
The FDA based the new use in higher-risk children and teens on immune response and safety results. In a study of those ages 2 through 17 who had completed a primary pediatric pneumococcal series, Capvaxive produced immune responses at least as strong as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the 12 shared strains. It also showed higher responses for the nine strains found only in this medicine.
Side effects were mostly mild to moderate and short-lived. Expected reactions, such as pain, redness, or swelling where you got the shot, along with symptoms like fatigue, headache, malaise, or crankiness, usually lasted a few days. The typical duration was about two days, and most cleared by day three. Serious side effects were uncommon and occurred at similar rates in both groups; one person fainted soon after vaccination, and that event was considered related.
There are no studies yet that directly measure how well Capvaxive prevents illness. The approval relies on immune response data in this at-risk group. Adult findings supported the overall picture. In adults 50 and older who had never received a pneumococcal vaccine, this medicine generated higher immune responses than a similar conjugate vaccine for many strains. In adults 18 to 49, responses to each tested strain met standards used to compare immune responses with those of adults 50 to 64 who received Capvaxive.
In previously vaccinated older adults, Capvaxive produced responses that were comparable to shared strains and higher for strains unique to this medicine. Compared with PPSV23, responses were comparable for shared strains and higher for strains unique to Capvaxive. In adults 18 to 64 at higher risk, responses after Capvaxive were similar to a Vaxneuvance plus PPSV23 series for shared strains and higher for strains unique to this medicine.
What Do I Need to Know?
You receive one intramuscular dose of 0.5 mL from a health care provider. Capvaxive is for people 2 to 17 years old who are at increased risk and who completed a primary pediatric pneumococcal series. Safety and effectiveness in those younger than 2 are not established.
Do not get Capvaxive if you have had a severe allergic reaction to any component of the vaccine or to diphtheria toxoid. Fainting can happen with injectable vaccines, so your health care provider may take steps to prevent injury. If you have a weakened immune system or take immunosuppressive therapy, your response may be lower, and vaccination may not protect everyone.
The most common reactions in higher-risk children 2 through 17 were pain, redness, and swelling where they got the shot, and symptoms such as fatigue, headache, malaise, and crankiness. These usually lasted only a few days. In a pediatric study, the overall safety profile was similar to that of the comparison vaccine.
In adults, getting Capvaxive with a seasonal flu shot led to immune responses that were not worse than giving them separately for most pneumococcal strains. Flu responses were also not worse for most strains when given with Capvaxive.
Pharmacist-summarized information indicates PCV21 can be given with several routine childhood vaccines without issues seen with safety or immune responses, including vaccines for diphtheria, tetanus, pertussis, rotavirus, hepatitis B, measles, mumps, rubella, and varicella. Clinics and pharmacies store Capvaxive in the refrigerator. Do not freeze it, and keep it protected from light. Ask for the FDA-approved Patient Information and review benefits and risks with your health care provider. You can report side effects to the Vaccine Adverse Event Reporting System (VAERS) by phone or online.